

This *Recommendations Summary* has been revised since its original publication. Namenda XR has been recommended by staff to remain a non-preferred drug and this recommendation has been approved by the Secretary.

MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary
November 5, 2014

In Attendance:

	Committee Member	Yes or No
1	Rosanne Barber	No
2	James Boblin M.D.	Yes
3	Ward Brown, M.D.	No
4	Catherine Decker PharmD	Yes
5	Ronald Diamond, M.D.	No
6	Lawrence Fleming M.D.	Yes
7	Kevin Izard M.D.	Yes
8	Steve Maike RPh	Yes
9	William E. Raduege, M.D.	Yes
10	Pat Towers	Yes
11	Alicia Walker PharmD	No
12	Michael Witkovsky M.D.	No

NOVEMBER 2014 THERAPEUTIC DRUG CLASS

ANTI-HISTAMINES, MINIMALLY SEDATING
BRONCHODILATORS, BETA AGONIST
COPD AGENTS
GLUCOCORTICOIDS, INHALED
LEUKOTRIENE MODIFIERS
COUGH AND COLD/NARCOTICS
EPINEPHRINE, SELF-INJECTED
INTRANASAL RHINITIS AGENTS
ANTIHYPERURICEMICS, ORAL
BILE SALTS
HISTAMINE II RECEPTOR BLOCKERS
OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS
OPHTHALMIC ANTIBIOTICS
OPHTHALMIC ANTI-INFLAMMATORIES
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
OPHTHALMICS, GLAUCOMA AGENTS
OTIC ANTIBIOTICS
OTIC ANTI-INFECTIVES
ANTIPSORIATICS, TOPICAL
IMMUNOMODULATORS FOR ATOPIC DERMATITIS
STERIODS, TOPICAL-LOW POTENCY
STERIODS, TOPICAL-MEDIUM POTENCY
STERIODS, TOPICAL-HIGH POTENCY
STERIODS, TOPICAL-VERY HIGH POTENCY
CYTOKINE AND CAM ANTAGONISTS
NSAIDS
NEUROPATHIC PAIN (ANALGESICS/ANESTHETICS TOPICAL AND FIBROMYALGIA)
ALZHEIMER'S AGENTS
ANTICONVULSANTS
ANTIDEPRESSANTS, OTHER
ANTIDEPRESSANTS, SSRIs
ANTIPARKINSON'S AGENTS
ANTIPSYCHOTICS
SEDATIVE HYPNOTICS
STIMULANTS AND RELATED AGENTS
GLUCOCORTICOIDS, ORAL-*NEW CLASS*

ANTIHISTAMINES, MINIMALLY SEDATING						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LORATADINE TABLETS OTC (ORAL)	38.6%	ON	Yes-Generic			
CETIRIZINE TABLETS OTC (ORAL)	35.3%	ON	Yes-Generic			
CETIRIZINE SOLUTION (ORAL)	11.2%	ON	Yes-Generic			
CETIRIZINE SOLUTION OTC (ORAL)	4.0%	ON	Yes-Generic			
LORATADINE SOLUTION OTC (ORAL)	6.3%	ON	Yes-Generic			
CETIRIZINE CHEWABLE OTC (ORAL)	0.0%	ON	Yes-Generic			
LEVOCETIRIZINE TABLETS (ORAL)	0.3%	OFF	No-Generic			
LORATADINE-D OTC (ORAL)	3.0%	ON	Yes-Generic			
CLARINEX SYRUP (ORAL)	0.0%	OFF	No			
CETIRIZINE-D OTC (ORAL)	1.2%	ON	Yes-Generic			
SEMPREX-D (ORAL)	0.0%	OFF	No			
CLARINEX TABLET (ORAL)	0.0%	OFF	No			
CLARINEX-D 12 HOUR (ORAL)	0.0%	OFF	No			
XYZAL SOLUTION (ORAL)	0.0%	OFF	No			
DESLORATADINE (ORAL)	0.1%	OFF	No-Generic			
LEVOCETIRIZINE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
DESLORATADINE ODT (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second – Steve Maike
 - All members were in favor of the motion.
 - Motion passes.

BRONCHODILATORS, BETA AGONIST						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FORADIL (INHALATION)	0.3%	ON	Yes			
STRIVERDI RESPIMAT (INHALATION)	0.0%	NR	No			
SEREVENT (INHALATION)	0.1%	OFF	No			
ARCAPTA NEOHALER (INHALATION)	0.0%	OFF	No			
ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)	14.3%	ON	Yes-Generic			
ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)	0.0%	ON	Yes-Generic			
XOPENEX NEB SOLN (INHALATION)	0.0%	OFF	No			
ALBUTEROL NEB SOLN 100 MG/20 ML (INHALATION)	0.2%	ON	Yes-Generic			
ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)	0.9%	OFF	No-Generic			
XOPENEX NEB SOLN CONC (INHALATION)	0.0%	OFF	No			
LEVALBUTEROL NEB SOLN CONC (INHALATION)	0.0%	OFF	No-Generic			
LEVALBUTEROL NEB SOLN (INHALATION)	0.3%	OFF	No-Generic			
METAPROTERENOL SYRUP (ORAL)	0.0%	OFF	No-Generic			
ALBUTEROL SYRUP (ORAL)	0.2%	ON	Yes-Generic			
METAPROTERENOL TABLET (ORAL)	0.0%	OFF	No-Generic			
TERBUTALINE (ORAL)	0.0%	ON	Yes-Generic			
ALBUTEROL ER (ORAL)	0.0%	ON	Yes-Generic			
ALBUTEROL TABLET (ORAL)	0.0%	ON	Yes-Generic			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second –Lawrence Fleming
 - All members were in favor of this motion.
 - Motion passes

COPD AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IPRATROPIUM NEBULIZER (INHALATION)	3.1%	ON	Yes-Generic			
IPRATROPIUM / ALBUTEROL (INHALATION)	16.6%	ON	Yes-Generic			
SPIRIVA (INHALATION)	46.9%	ON	Yes			
ATROVENT HFA (INHALATION)	4.5%	ON	Yes			
COMBIVENT RESPIMAT (INHALATION)	25.9%	ON	Yes			
DALIRESP (ORAL)	2.2%	ON	Yes			
TUDORZA PRESSAIR (INHALATION)	0.8%	OFF	No			
ANORO ELLIPTA (INHALATION)	0.0%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second – Pat Towers
 - All members were in favor of this motion
 - Motion passes

GLUCOCORTICOID, INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DULERA (INHALATION)	3.1%	ON	Yes			
ADVAIR DISKUS (INHALATION)	36.6%	ON	Yes			
SYMBICORT (INHALATION)	15.1%	ON	Yes			
ADVAIR HFA (INHALATION)	5.1%	ON	No			
BREO ELLIPTA (INHALATION)	0.0%	OFF	No			
ASMANEX (INHALATION)	1.4%	ON	Yes			
QVAR (INHALATION)	7.0%	ON	Yes			
FLOVENT DISKUS (INHALATION)	0.8%	ON	Yes			
FLOVENT HFA (INHALATION)	23.9%	ON	Yes			
PULMICORT FLEXHALER (INHALATION)	1.2%	ON	Yes			
ALVESCO (INHALATION)	0.1%	OFF	No			
AEROSPAN (INHALATION)	0.0%	NR	No			
PULMICORT 0.25, 0.5 MG RESPULES (INHALATION)	0.6%	ON	Yes			
BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)	4.7%	OFF	No-Generic			
PULMICORT 1 MG RESPULES (INHALATION)	0.4%	ON	Yes			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second – William Raduege
 - All members were in favor of the motion.
 - Motion passes.

LEUKOTRIENE MODIFIERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MONTELUKAST TABLET (ORAL)	59.7%	ON	Yes-Generic			
MONTELUKAST CHEWABLE TABLET (ORAL)	39.9%	ON	Yes-Generic			
ZAFIRLUKAST (ORAL)	0.2%	OFF	No-Generic			
MONTELUKAST GRANULES (ORAL)	0.2%	OFF	No-Generic			
ZYFLO (ORAL)	0.0%	OFF	No			
ZYFLO CR (ORAL)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second – Steve Maike
 - All members were in favor of the motion.
 - Motion passes.

COUGH AND COLD, NARCOTIC						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PROMETHAZINE/CODEINE SYRUP (ORAL)	43.9%	ON	Yes-Generic			
REZIRA SOLUTION (ORAL)	0.0%	OFF	No			
TUSSIONEX SUSPENSION ER 12H (ORAL)	0.0%	OFF	No			
GUAIFENESIN/CODEINE LIQUID (ORAL)	10.5%	ON	Yes-Generic			
GUAIFENESIN/CODEINE LIQUID OTC (ORAL)	43.8%	ON	Yes-Generic			
ZUTRIPRO SOLUTION (ORAL)	0.0%	OFF	No			
HYDROCODONE/HOMATROPINE SYRUP (ORAL)	0.1%	OFF	No-Generic			
PROMETHAZINE/PHENYLEPHRINE/CODEINE (QUALITEST) SYRUP (ORA	1.0%	ON	Yes-Generic			
HYDROCODONE/CHLORPHENIRAMINE SUSPENSION ER 12H (ORAL)	0.7%	OFF	No-Generic			
PSE/HYDROCODONE/CHLORPHENIRAMINE SOLUTION (ORAL)	0.0%	NR	No-Generic			
VITUZ SOLUTION (ORAL)	0.0%	OFF	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second – William Radeuge
 - All members were in favor of this motion
 - Motion passes

EPINEPHRINE, SELF-INJECTED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPINEPHRINE (AG) (INJECTION)	0.0%	OFF	No			
AUVI-Q (INTRAMUSC)	0.0%	OFF	No			
EPIPEN JR (INTRAMUSC)	23.1%	ON	Yes			
EPIPEN (INTRAMUSC)	76.8%	ON	Yes			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.

- Second –Catherine Decker
- All members were in favor of this motion.
- Motion passes

INTRANASAL RHINITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NASONEX (NASAL)	14.5%	ON	Yes			
RHINOCORT AQUA (NASAL)	0.1%	OFF	No			
OMNARIS (NASAL)	0.1%	OFF	No			
FLUTICASONE (NASAL)	79.2%	ON	Yes-Generic			
PATANASE (NASAL)	0.9%	ON	Yes			
ASTEPRO (NASAL)	1.1%	ON	Yes			
BECONASE AQ (NASAL)	0.3%	ON	Yes			
IPRATROPIUM (NASAL)	1.9%	ON	Yes-Generic			
ZETONNA (NASAL)	0.1%	OFF	No			
QNASL (NASAL)	0.2%	OFF	No			
VERAMYST (NASAL)	0.4%	OFF	No			
FLUNISOLIDE (NASAL)	0.0%	OFF	No-Generic			
NASACORT AQ (NASAL)	0.0%	OFF	No			
AZELASTINE (ASTELIN) (NASAL)	0.8%	OFF	No-Generic			
BUDESONIDE (AG) (NASAL)	0.0%	OFF	No-Generic			
DYMISTA (NASAL)	0.1%	OFF	No			
AZELASTINE (ASTEPRO) (NASAL)	0.1%	OFF	No-Generic			
TRIAMCINOLONE (NASAL)	0.1%	OFF	No-Generic			
BUDESONIDE (NASAL)	0.1%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

ANTIHYPERTENSIVES, SYMPATHOLYTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLONIDINE (ORAL)	65.4%	ON	Yes-Generic			
GUANFACINE (ORAL)	30.1%	ON	Yes-Generic			
METHYLDOPA (ORAL)	1.1%	ON	Yes-Generic			
CATAPRES-TTS (TRANSDERM)	3.0%	ON	Yes			
RESERPINE (ORAL)	0.0%	OFF	No-Generic			
METHYLDOPA/HYDROCHLOROTHIAZIDE (ORAL)	0.0%	OFF	No-Generic			
CLOPPRES (ORAL)	0.0%	OFF	No-Generic			
CLONIDINE (TRANSDERM)	0.4%	OFF	No-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

ANTHYPERURICEMICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALLOPURINOL (ORAL)	81.9%	ON	Yes-Generic			
PROBENECID / COLCHICINE (ORAL)	3.2%	ON	Yes-Generic			
PROBENECID (ORAL)	1.5%	ON	Yes-Generic			
ULORIC (ORAL)	6.5%	OFF	No			
COLCRYS (ORAL)	6.8%	OFF	No			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
 - Second –Pat Towers
 - All members were in favor of this motion.
 - Motion passes

BILE SALTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
URSODIOL 300 MG CAPSULE (ORAL)	78.2%	ON	Yes-Generic			
URSODIOL TABLET (ORAL)	21.8%	ON	Yes-Generic			
CHENODAL (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes

HISTAMINE II RECEPTOR BLOCKER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FAMOTIDINE TABLET (ORAL)	20.6%	ON	Yes-Generic			
RANITIDINE SYRUP (ORAL)	17.7%	ON	Yes-Generic			
RANITIDINE TABLET (ORAL)	59.6%	ON	Yes-Generic			
CIMETIDINE TABLET (ORAL)	1.2%	ON	Yes-Generic			
CIMETIDINE SOLUTION (ORAL)	0.2%	ON	Yes-Generic			
NIZATIDINE CAPSULE (ORAL)	0.1%	OFF	No-Generic			
RANITIDINE CAPSULE (ORAL)	0.0%	OFF	No-Generic			
NIZATIDINE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
FAMOTIDINE SUSPENSION (ORAL)	0.5%	OFF	No-Generic			

- Discussion: None

- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Pat Towers
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PRED-G DROPS SUSP (OPHTHALMIC)	0.2%	ON	Yes			
TOBRADEX SUSPENSION (OPHTHALMIC)	33.9%	ON	Yes			
ZYLET (OPHTHALMIC)	0.7%	OFF	No			
BLEPHAMIDE S.O.P. (OPHTHALMIC)	1.1%	ON	Yes-Generic			
TOBRADEX OINTMENT (OPHTHALMIC)	15.6%	ON	Yes			
PRED-G OINT. (OPHTHALMIC)	0.1%	ON	Yes			
BLEPHAMIDE (OPHTHALMIC)	1.3%	ON	Yes			
NEOMYCIN/POLYMYXIN/DEXAMETHASONE (OPHTHALMIC)	44.4%	ON	Yes-Generic			
SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)	2.5%	ON	Yes-Generic			
NEOMYCIN/BACITRACIN/POLY/HC (OPHTHALMIC)	0.0%	OFF	No-Generic			
TOBRADEX ST (OPHTHALMIC)	0.0%	OFF	No			
TOBRAMYCIN / DEXAMETHASONE SUSPENSION (OPHTHALMIC)	0.2%	OFF	No-Generic			
NEOMYCIN/POLYMYXIN/HC (OPHTHALMIC)	0.0%	OFF	No-Generic			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMIC ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CIPROFLOXACIN SOLUTION (OPHTHALMIC)	9.9%	ON	Yes-Generic			
OFLOXACIN (OPHTHALMIC)	6.1%	ON	Yes-Generic			
GENTAMICIN DROPS (OPHTHALMIC)	8.4%	ON	Yes-Generic			
POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)	27.7%	ON	Yes-Generic			
MOXEZA (OPHTHALMIC)	0.4%	ON	Yes			
VIGAMOX (OPHTHALMIC)	12.6%	ON	Yes			
TOBRAMYCIN (OPHTHALMIC)	6.8%	ON	Yes-Generic			
TOBREX OINTMENT (OPHTHALMIC)	0.5%	ON	Yes			
ERYTHROMYCIN (OPHTHALMIC)	22.4%	ON	Yes-Generic			
CILOXAN OINTMENT (OPHTHALMIC)	0.2%	ON	Yes			
GENTAMICIN OINT. (OPHTHALMIC)	1.2%	ON	Yes-Generic			
BACITRACIN/POLYMYXIN B SULFATE OINT. (OPHTHALMIC)	0.0%	OFF	No-Generic			
AZASITE (OPHTHALMIC)	0.0%	OFF	No			
GARAMYCIN OINT. (OPHTHALMIC)	0.0%	ON	No-Generic			
ZYMAXID (OPHTHALMIC)	0.0%	OFF	No			
BESIVANCE (OPHTHALMIC)	0.0%	OFF	No			
NEOMYCIN/BACITRACIN/POLYMYXIN OINT (OPHTHALMIC)	0.0%	OFF	No-Generic			
NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)	0.0%	OFF	No-Generic			
SULFACETAMIDE OINTMENT (OPHTHALMIC)	0.1%	ON	Yes-Generic			
BACITRACIN (OPHTHALMIC)	0.0%	OFF	No-Generic			
SULFACETAMIDE SOLUTION (OPHTHALMIC)	3.7%	ON	Yes-Generic			
LEVOFLOXACIN (OPHTHALMIC)	0.0%	OFF	No-Generic			
GATIFLOXACIN (OPHTHALMIC)	0.0%	NR	No-Generic			
NATACYN (OPHTHALMIC)	0.0%	OFF	No			

- Discussion: None

- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMICS, ANTI-INFLAMMATORIES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FLUOROMETHOLONE (OPHTHALMIC)	6.1%	ON	Yes-Generic			
FLAREX (OPHTHALMIC)	0.0%	ON	Yes			
PRED MILD (OPHTHALMIC)	0.7%	ON	Yes			
LOTEMAX DROPS (OPHTHALMIC)	3.2%	ON	Yes			
FML S.O.P. (OPHTHALMIC)	0.4%	ON	Yes			
FLURBIPROFEN (OPHTHALMIC)	0.4%	ON	Yes-Generic			
KETOROLAC (OPHTHALMIC)	16.3%	ON	Yes-Generic			
DICLOFENAC (OPHTHALMIC)	0.1%	OFF	No-Generic			
MAXIDEX (OPHTHALMIC)	0.1%	ON	Yes			
FML FORTE (OPHTHALMIC)	0.5%	ON	Yes			
DEXAMETHASONE (OPHTHALMIC)	2.0%	ON	Yes-Generic			
DUREZOL (OPHTHALMIC)	6.6%	ON	Yes			
KETOROLAC LS (OPHTHALMIC)	6.7%	ON	Yes-Generic			
ILEVRO (OPHTHALMIC)	0.0%	OFF	No			
NEVANAC (OPHTHALMIC)	0.0%	OFF	No			
VEXOL (OPHTHALMIC)	0.1%	OFF	No			
PREDNISOLONE SOD PHOSPHATE (OPHTHALMIC)	0.0%	OFF	Yes-Generic			
PROLENSA (OPHTHALMIC)	0.0%	OFF	No			
LOTEMAX OINTMENT (OPHTHALMIC)	0.1%	OFF	No			
LOTEMAX GEL (OPHTHALMIC)	0.9%	OFF	No			
PREDNISOLONE ACETATE (OPHTHALMIC)	55.4%	ON	Yes-Generic			
ACUVAIL (OPHTHALMIC)	0.0%	OFF	No			
BROMFENAC (OPHTHALMIC)	0.3%	OFF	No-Generic			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BEPREVE (OPHTHALMIC)	0.0%	OFF	No			
ALREX (OPHTHALMIC)	1.7%	ON	Yes			
KETOTIFEN OTC (OPHTHALMIC)	16.3%	ON	Yes-Generic			
ZADITOR OTC (OPHTHALMIC)	2.1%	ON	Yes-Generic			
PATADAY (OPHTHALMIC)	76.2%	ON	Yes			
EMADINE (OPHTHALMIC)	0.0%	OFF	No			
PATANOL (OPHTHALMIC)	0.5%	OFF	No			
LASTACFT (OPHTHALMIC)	0.2%	OFF	No			
AZELASTINE (OPHTHALMIC)	0.1%	OFF	No-Generic			
EPINASTINE (OPHTHALMIC)	0.1%	OFF	No-Generic			
CROMOLYN SODIUM (OPHTHALMIC)	2.9%	ON	Yes-Generic			
ALOMIDE (OPHTHALMIC)	0.0%	OFF	No			
ALOCRI (OPHTHALMIC)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

OPHTHALMICS, GLAUCOMA AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IOPIDINE (OPHTHALMIC)	0.0%	OFF	No			
ALPHAGAN P 0.15% (OPHTHALMIC)	4.5%	ON	Yes			
BRIMONIDINE (OPHTHALMIC)	4.5%	ON	Yes-Generic			
ALPHAGAN P 0.1% (OPHTHALMIC)	0.3%	OFF	No			
APRACLOUIDINE (OPHTHALMIC)	0.0%	OFF	No-Generic			
BRIMONIDINE P 0.15% (OPHTHALMIC)	0.1%	OFF	No-Generic			
BETIMOL (OPHTHALMIC)	0.3%	ON	Yes			
BETOPTIC S (OPHTHALMIC)	0.7%	ON	Yes			
CARTEOLOL (OPHTHALMIC)	0.2%	ON	Yes-Generic			
BETAXOLOL (OPHTHALMIC)	0.1%	ON	Yes-Generic			
ISTALOL (OPHTHALMIC)	0.0%	OFF	No			
TIMOLOL (OPHTHALMIC)	13.6%	ON	Yes-Generic			
METIPRANOLOL (OPHTHALMIC)	0.1%	ON	Yes-Generic			
COMBIGAN (OPHTHALMIC)	5.5%	ON	Yes			
LEVOBUNOLOL (OPHTHALMIC)	0.7%	ON	Yes-Generic			
TIMOPTIC OCUDOSE (OPHTHALMIC)	0.1%	OFF	No			
AZOPT (OPHTHALMIC)	3.1%	ON	Yes			
SIMBRINZA (OPHTHALMIC)	0.6%	ON	Yes			
DORZOLAMIDE (OPHTHALMIC)	2.5%	ON	Yes-Generic			
DORZOLAMIDE / TIMOLOL (OPHTHALMIC)	7.8%	ON	Yes-Generic			
COSOPT PF (OPHTHALMIC)	0.4%	ON	Yes			
TRAVATAN Z 2.5 ML (OPHTHALMIC)	25.2%	ON	Yes			
RESCULA (OPHTHALMIC)	0.0%	OFF	No			
LATANOPROST 2.5 ML (OPHTHALMIC)	23.4%	ON	Yes-Generic			
TRAVATAN Z 5 ML (OPHTHALMIC)	3.8%	ON	Yes			
LUMIGAN 2.5ML (OPHTHALMIC)	1.1%	OFF	No			
LUMIGAN 5ML (OPHTHALMIC)	0.2%	OFF	No			
ZIOPTAN (OPHTHALMIC)	0.4%	OFF	No			
TRAVOPROST 2.5 ML (OPHTHALMIC)	0.0%	OFF	No-Generic			
TRAVOPROST 5 ML (OPHTHALMIC)	0.0%	OFF	No-Generic			
PILOCARPINE (OPHTHALMIC)	0.8%	ON	Yes-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Pat Towers
 - All members were in favor of this motion.
 - Motion passes

OTIC ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OFLOXACIN (OTIC)	29.6%	ON	Yes-Generic			
CIPRO HC (OTIC)	4.7%	ON	Yes			
NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)	31.9%	ON	Yes-Generic			
COLY-MYCIN S (OTIC)	0.0%	ON	Yes			
CORTISPORIN-TC (OTIC)	0.0%	OFF	No			
CIPRODEX (OTIC)	33.7%	ON	No			

- Discussion: Kevin Izard indicated concern with moving ciprodex to non-preferred, due to the approved use for ruptured tympanic membrane and use with tympanostomy tubes. Rick Pope stated that the 2013 American Academy of Pediatrics clinical practice guidelines do not distinguish between products to be used with regards to tympanic tubes.
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –William Raduege.
 - The vote was 6-1 in favor of the motion. Kevin Izard opposed the motion.
 - Motion passes

OTIC ANTI-INFECTIVES & ANESTHETICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ANTIPYRINE / BENZOCAINE (OTIC)	96.5%	ON	Yes-Generic			
OTOZIN (OTIC)	0.0%	OFF	No-Generic			
ACETIC ACID (OTIC)	3.2%	ON	Yes-Generic			
ACETIC ACID/ALUMINUM (OTIC)	0.0%	OFF	No-Generic			
ACETIC ACID HC (OTIC)	0.2%	OFF	No-Generic			
PINNACAINE (OTIC)	0.0%	OFF	No-Generic			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

ANTIPSORIATICS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OXSORALEN-ULTRA (ORAL)	0.0%	ON	Yes			
SORIATANE (ORAL)	93.6%	ON	Yes			
8-MOP (ORAL)	0.0%	ON	Yes			
ACITRETIN (AG) (ORAL)	2.6%	OFF	No-Generic			
ACITRETIN (ORAL)	3.8%	OFF	No-Generic			
METHOXSALLEN RAPID (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard

- All members were in favor of this motion.
- Motion passes

ANTIPSORIATICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VECTICAL (TOPICAL)	6.3%	ON	Yes			
TACLONEX SCALP (TOPICAL)	4.9%	ON	Yes			
CALCIPOTRIENE SOLUTION (TOPICAL)	8.9%	ON	Yes-Generic			
CALCITRIOL OINTMENT (TOPICAL)	0.0%	OFF	No-Generic			
SORILUX (TOPICAL)	0.0%	OFF	No			
CALCITRENE (TOPICAL)	9.9%	ON	Yes-Generic			
TACLONEX OINTMENT (TOPICAL)	10.2%	ON	Yes			
CALCIPOTRIENE/BETAMETHASONE OINTMENT (AG) (TOPICAL)	2.1%	NR	No-Generic			
CALCIPOTRIENE OINTMENT (TOPICAL)	3.6%	OFF	No-Generic			
CALCIPOTRIENE CREAM (TOPICAL)	53.9%	ON	Yes-Generic			
CALCIPOTRIENE/BETAMETHASONE OINTMENT (TOPICAL)	0.3%	NR	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

IMMUNOMODULATORS, ATOPIC DERMATITIS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ELIDEL (TOPICAL)	80.0%	ON	Yes			
PROTOPIC (TOPICAL)	20.0%	OFF	No			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
 - Second –Pat Towers
 - All members were in favor of this motion.
 - Motion passes

IMMUNOMODULATORS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALDARA (TOPICAL)	97.2%	ON	Yes			
IMIQUIMOD (TOPICAL)	2.6%	OFF	No-Generic			
ZYCLARA (TOPICAL)	0.2%	OFF	No			

- Discussion: None

- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

STEROIDS, TOPICAL LOW						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HYDROCORTISONE CREAM OTC (TOPICAL)	6.9%	ON	Yes-Generic			
SCALPICIN OTC (TOPICAL)	0.0%	ON	Yes-Generic			
HYDROCORTISONE CREAM (TOPICAL)	40.9%	ON	Yes-Generic			
HYDROCORTISONE LOTION OTC (TOPICAL)	0.8%	ON	Yes-Generic			
HYDROCORTISONE OINTMENT OTC (TOPICAL)	1.3%	ON	Yes-Generic			
HYDROCORTISONE / MIN OIL / PET OINTMENT (TOPICAL)	0.0%	ON	Yes-Generic			
HYDROCORTISONE OINTMENT (TOPICAL)	38.2%	ON	Yes-Generic			
TEXACORT (TOPICAL)	0.0%	OFF	No-Generic			
VERDESO (TOPICAL)	0.0%	OFF	No			
HYDROCORTISONE ACETATE / UREA (TOPICAL)	0.0%	OFF	No-Generic			
HYDROCORTISONE/ALOE GEL (TOPICAL)	0.0%	OFF	No-Generic			
HYDROCORTISONE LOTION (TOPICAL)	1.8%	ON	Yes-Generic			
ALCLOMETASONE DIPROPIONATE CREAM (TOPICAL)	2.6%	ON	No-Generic			
ALCLOMETASONE DIPROPIONATE OINTMENT (TOPICAL)	3.4%	ON	No-Generic			
CAPEX SHAMPOO (TOPICAL)	0.0%	OFF	No			
DESONATE GEL (TOPICAL)	0.0%	OFF	No			
FLUOCINOLONE 0.01% OIL (TOPICAL)	3.1%	ON	Yes-Generic			
DERMA-SMOOTHIE-FS (TOPICAL)	0.0%	OFF	No			
DESONIDE CREAM (TOPICAL)	0.5%	OFF	No-Generic			
DESONIDE OINTMENT (TOPICAL)	0.4%	OFF	No-Generic			
DESONIDE LOTION (TOPICAL)	0.1%	OFF	No-Generic			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

STEROIDS, TOPICAL MEDIUM						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PANDEL (TOPICAL)	0.0%	OFF	No			
HYDROCORTISONE BUTYRATE SOLUTION BRAND (TOPICAL)	0.0%	OFF	No-Generic			
MOMETASONE FUROATE SOLUTION (TOPICAL)	2.5%	ON	Yes-Generic			
MOMETASONE FUROATE CREAM (TOPICAL)	7.7%	ON	Yes-Generic			
MOMETASONE FUROATE OINTMENT (TOPICAL)	3.8%	ON	Yes-Generic			
SYNALAR SOLUTION (TOPICAL)	0.0%	OFF	No			
FLUTICASONE PROPIONATE CREAM (TOPICAL)	37.0%	ON	Yes-Generic			
HYDROCORTISONE BUTYRATE OINTMENT BRAND (TOPICAL)	0.0%	OFF	No-Generic			
FLUTICASONE PROPIONATE OINTMENT (TOPICAL)	12.9%	ON	Yes-Generic			
DERMATOP CREAM (TOPICAL)	0.0%	OFF	No			
DERMATOP OINTMENT (TOPICAL)	0.0%	OFF	No			
HYDROCORTISONE BUTYRATE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
CLOCORTOLONE CREAM (AG) (TOPICAL)	0.0%	NR	No-Generic			
HYDROCORTISONE BUTYRATE CREAM BRAND (TOPICAL)	0.0%	OFF	No-Generic			
PREDNICARBATE OINTMENT (TOPICAL)	0.0%	OFF	No-Generic			
PREDNICARBATE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
FLUOCINOLONE ACETONIDE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
LUXIQ (TOPICAL)	0.0%	OFF	No			
FLUOCINOLONE ACETONIDE OINTMENT (TOPICAL)	0.2%	OFF	No-Generic			
SYNALAR CREAM (TOPICAL)	0.0%	OFF	No			
FLUOCINOLONE ACETONIDE SOLUTION (TOPICAL)	0.5%	OFF	No-Generic			
HYDROCORTISONE VALERATE CREAM (TOPICAL)	21.3%	ON	No-Generic			
HYDROCORTISONE BUTYRATE OINTMENT (TOPICAL)	0.1%	OFF	No-Generic			
CLODERM (TOPICAL)	0.0%	OFF	No			
HYDROCORTISONE VALERATE OINTMENT (TOPICAL)	12.7%	ON	No-Generic			
HYDROCORTISONE BUTYRATE SOLUTION (TOPICAL)	0.0%	OFF	No-Generic			
HYDROCORTISONE BUTYRATE/EMOLLIENT (TOPICAL)	0.0%	OFF	No-Generic			
HYDROCORTISONE BUTYRATE/EMOLLIENT (AG) (TOPICAL)	0.0%	OFF	No-Generic			
BETAMETHASONE VALERATE FOAM (TOPICAL)	0.8%	OFF	No-Generic			
FLUTICASONE PROPIONATE LOTION (TOPICAL)	0.0%	OFF	No-Generic			
CORDRAN TAPE (TOPICAL)	0.4%	OFF	No			
CUTIVATE LOTION (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

STEROIDS, TOPICAL HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)	50.2%	ON	Yes-Generic			
BETAMET DIPROP / PROP GLY CREAM (TOPICAL)	0.7%	ON	No-Generic			
FLUOCINONIDE EMOLLIENT (TOPICAL)	0.5%	ON	Yes-Generic			
TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)	30.4%	ON	Yes-Generic			
BETAMETHASONE VALERATE OINTMENT (TOPICAL)	1.4%	ON	Yes-Generic			
BETAMETHASONE VALERATE CREAM (TOPICAL)	1.5%	ON	Yes-Generic			
BETAMETHASONE DIPROPIONATE LOTION (TOPICAL)	1.1%	ON	No-Generic			
TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)	0.1%	OFF	Yes-Generic			
KENALOG AEROSOL (TOPICAL)	0.0%	OFF	No			
FLUOCINONIDE OINTMENT (TOPICAL)	4.1%	ON	Yes-Generic			
HALOG OINTMENT (TOPICAL)	0.0%	OFF	No			
BETAMETHASONE VALERATE LOTION (TOPICAL)	0.7%	ON	Yes-Generic			
FLUOCINONIDE CREAM (TOPICAL)	2.8%	ON	Yes-Generic			
FLUOCINONIDE GEL (TOPICAL)	0.3%	ON	Yes-Generic			
BETAMETHASONE DIPROPIONATE CREAM (TOPICAL)	2.6%	ON	No-Generic			
FLUOCINONIDE SOLUTION (TOPICAL)	1.3%	ON	Yes-Generic			
BETAMETHASONE DIPROPIONATE OINTMENT (TOPICAL)	1.4%	ON	No-Generic			
HALOG CREAM (TOPICAL)	0.0%	OFF	No			
BETAMETHASONE DIPROPIONATE GEL (TOPICAL)	0.0%	ON	No-Generic			
BETAMET DIPROP / PROP GLY LOTION (TOPICAL)	0.2%	ON	No-Generic			
BETAMET DIPROP / PROP GLY OINTMENT (TOPICAL)	0.5%	ON	No-Generic			
DIFLORASONE DIACETATE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
DIFLORASONE DIACETATE OINTMENT (TOPICAL)	0.0%	OFF	No-Generic			
DESOXIMETASONE CREAM (TOPICAL)	0.1%	OFF	No-Generic			
TRIANEX OINTMENT (TOPICAL)	0.0%	OFF	No-Generic			
AMCINONIDE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
DESOXIMETASONE GEL (TOPICAL)	0.0%	OFF	No-Generic			
AMCINONIDE OINTMENT (TOPICAL)	0.0%	OFF	No-Generic			
TOPICORT SPRAY (TOPICAL)	0.0%	OFF	No			
DESOXIMETASONE OINTMENT (TOPICAL)	0.1%	OFF	No-Generic			
AMCINONIDE LOTION (TOPICAL)	0.0%	OFF	No-Generic			
VANOS (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

STEROIDS, TOPICAL VERY HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOBETASOL PROPIONATE SOLUTION (TOPICAL)	21.0%	ON	Yes-Generic			
CLOBETASOL PROPIONATE CREAM (TOPICAL)	30.2%	ON	Yes-Generic			
CLOBETASOL PROPIONATE OINTMENT (TOPICAL)	42.3%	ON	Yes-Generic			
CLOBETASOL PROPIONATE GEL (TOPICAL)	1.8%	ON	Yes-Generic			
CLOBETASOL EMOLLIENT (TOPICAL)	2.3%	ON	Yes-Generic			
CLOBEX SHAMPOO (TOPICAL)	0.8%	ON	Yes			
HALOBETASOL PROPIONATE OINTMENT (TOPICAL)	0.4%	OFF	Yes-Generic			
CLOBEX LOTION (TOPICAL)	0.4%	ON	Yes			
HALOBETASOL PROPIONATE CREAM (TOPICAL)	0.2%	OFF	Yes-Generic			
OLUX-E (TOPICAL)	0.0%	OFF	No			
CLOBEX SPRAY (TOPICAL)	0.2%	OFF	No			
CLOBETASOL PROPIONATE FOAM (TOPICAL)	0.3%	OFF	No-Generic			
CLOBETASOL LOTION (TOPICAL)	0.1%	OFF	No-Generic			
CLOBETASOL SHAMPOO (TOPICAL)	0.1%	OFF	No-Generic			
APEXICON E (TOPICAL)	0.0%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Lawrence Fleming
 - All members were in favor of this motion.
 - Motion passes

CYTOKINE AND CAM ANTAGONISTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ENBREL KIT (INJECTION)	1.1%	ON	Yes			
SIMPONI SYRINGE (INJECTION)	0.2%	OFF	No			
ENBREL PEN (INJECTION)	20.2%	ON	Yes			
KINERET (INJECTION)	0.6%	OFF	No			
CIMZIA SYRINGE KIT (INJECTION)	7.0%	ON	Yes			
CIMZIA KIT (INJECTION)	0.4%	ON	Yes			
XELJANZ (ORAL)	0.3%	OFF	No			
SIMPONI PEN INJECTER (INJECTION)	0.5%	OFF	No			
HUMIRA PEN KIT (INJECTION)	50.7%	ON	Yes			
HUMIRA KIT (INJECTION)	9.2%	ON	Yes			
ENBREL SYRINGE (INJECTION)	7.2%	ON	Yes			
ORENCIA SYRINGE (SUBCUTANE.)	1.9%	OFF	No			
ACTEMRA SYRINGE (SUBCUTANE.)	0.4%	NR	No			
OTEZLA (ORAL)	0.0%	NR	No			
STELARA SYRINGE (INJECTION)	0.4%	OFF	No			

- Discussion: Kevin Izard stated that there was much discussion amongst the committee regarding this class. Kevin Izard reviewed the American College of Rheumatology guidelines, and in most cases, they recommend a DMARD for first line use, rather than a biologic. Based on the guidelines, the recommendations and PA criteria are consistent. Kevin Izard confirmed with staff that there are PA mechanisms to request consideration of special circumstances. Steve Maike commented that commercial PBMs and Medicare Part D plans are tougher. Most payers only have one preferred agent. The Wisconsin Medicaid PDL offers at least two or more preferred products for each indication. Steve Maike stated that he felt comfortable with the variety of options that three preferred products provide.
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –Steve Maike
 - All members were in favor of this motion.
 - Motion passes

NSAIDS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IBUPROFEN TABLET OTC (ORAL)	1.2%	ON	Yes-Generic			
MELOXICAM TABLET (ORAL)	13.2%	ON	Yes-Generic			
MOBIC SUSPENSION (ORAL)	0.0%	OFF	No			
NAPROXEN SODIUM OTC (ORAL)	0.4%	ON	Yes-Generic			
NAPROXEN TABLET (ORAL)	16.3%	ON	Yes-Generic			
IBUPROFEN TABLET (ORAL)	32.6%	ON	Yes-Generic			
NAPROXEN SODIUM (ORAL)	1.1%	ON	Yes-Generic			
ADVIL OTC (ORAL)	0.0%	ON	Yes-Generic			
VOLTAREN (TOPICAL)	5.6%	ON	Yes			
IBUPROFEN CAPSULE OTC (ORAL)	0.0%	ON	Yes-Generic			
ADVIL MIGRAINE CAPSULE OTC (ORAL)	0.0%	ON	Yes			
IBUPROFEN DROPS SUSPENSION OTC (ORAL)	0.0%	ON	Yes-Generic			
ADVIL TAB CHEW OTC (ORAL)	0.0%	ON	Yes			
INDOMETHACIN CAPSULE (ORAL)	2.1%	ON	Yes-Generic			
IBUPROFEN TAB CHEW OTC (ORAL)	0.0%	ON	Yes-Generic			
KETOROLAC (ORAL)	1.7%	ON	Yes-Generic			
IBUPROFEN SUSPENSION OTC (ORAL)	1.0%	ON	Yes-Generic			
NAPROXEN EC (ORAL)	0.5%	ON	Yes-Generic			
IBUPROFEN SUSPENSION (ORAL)	9.6%	ON	Yes-Generic			
SULINDAC (ORAL)	0.4%	ON	Yes-Generic			
DICLOFENAC SR (ORAL)	0.2%	ON	Yes-Generic			
NAPROXEN SUSPENSION (ORAL)	0.2%	ON	Yes-Generic			
NABUMETONE (ORAL)	1.2%	ON	Yes-Generic			
NAPRELAN (ORAL)	0.0%	OFF	No			
INDOCIN SUSPENSION (ORAL)	0.0%	OFF	No			
FLURBIPROFEN (ORAL)	0.1%	ON	Yes-Generic			
DICLOFENAC SODIUM (ORAL)	7.5%	ON	Yes-Generic			
DICLOFENAC POTASSIUM (ORAL)	0.9%	ON	Yes-Generic			
KETOPROFEN (ORAL)	0.3%	ON	Yes-Generic			
VIMOVO (ORAL)	0.0%	OFF	No			
MELOXICAM SUSPENSION (ORAL)	0.0%	OFF	No-Generic			
DUEXIS (ORAL)	0.0%	OFF	No			
PENNSAID SOLUTION (TOPICAL)	0.0%	OFF	No			
ETODOLAC (ORAL)	0.9%	ON	No-Generic			
PONSTEL (ORAL)	0.0%	OFF	No			
PIROXICAM (ORAL)	0.9%	ON	No-Generic			
CELEBREX (ORAL)	2.0%	OFF	No			
TOLMETIN SODIUM CAPSULE (ORAL)	0.0%	OFF	No-Generic			
DIFLUNISAL (ORAL)	0.0%	OFF	No-Generic			
SPRIX (NASAL)	0.0%	OFF	No			
FLECTOR (TOPICAL)	0.1%	OFF	No			
ZORVOLEX (ORAL)	0.0%	NR	No			
NALFON (ORAL)	0.0%	OFF	No			
INDOMETHACIN CAPSULE ER (ORAL)	0.0%	OFF	No-Generic			
ETODOLAC TAB SR (ORAL)	0.0%	OFF	No-Generic			
TOLMETIN SODIUM TABLET (ORAL)	0.0%	OFF	No-Generic			
FENOPROFEN (ORAL)	0.0%	NR	No-Generic			
ZIPSOR (ORAL)	0.0%	OFF	No			
DICLOFENAC SODIUM/MISOPROSTOL (ORAL)	0.0%	OFF	No-Generic			
OXAPROZIN (ORAL)	0.0%	OFF	No-Generic			
DICLOFENAC SOLUTION (TOPICAL)	0.0%	OFF	No-Generic			
MECLOFENAMATE (ORAL)	0.0%	OFF	No-Generic			
PENNSAID PUMP (TOPICAL)	0.0%	NR	No			
KETOPROFEN ER (ORAL)	0.0%	OFF	No-Generic			
INDOCIN (RECTAL)	0.0%	ON	No-Generic			
MEFENAMIC ACID (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

NEUROPATHIC PAIN						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GABAPENTIN CAPSULE (ORAL)	43.4%	ON	Yes-Generic			
LIDODERM (TOPICAL)	4.8%	ON	Yes			
CAPSAICIN OTC (TOPICAL)	0.3%	ON	Yes-Generic			
ZOSTRIX OTC (TOPICAL)	0.0%	ON	Yes-Generic			
GRALISE (ORAL)	0.0%	OFF	No			
GABAPENTIN TABLET (ORAL)	13.9%	ON	Yes-Generic			
SAVELLA DOSE PACK (ORAL)	0.1%	ON	Yes			
SAVELLA (ORAL)	1.5%	ON	Yes			
LIDOCAINE (AG) (TOPICAL)	0.0%	NR	No-Generic			
LYRICA CAPSULE (ORAL)	16.2%	ON	Yes			
GABAPENTIN SOLUTION (ORAL)	0.6%	ON	Yes-Generic			
DULOXETINE (AG) (ORAL)	0.0%	NR	Yes-Generic			
HORIZANT (ORAL)	0.0%	OFF	No			
DULOXETINE (ORAL)	18.6%	NR	Yes-Generic			
LIDOCAINE (TOPICAL)	0.4%	NR	No-Generic			
LYRICA SOLUTION (ORAL)	0.0%	ON	Yes			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

ALZHEIMER'S AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DONEPEZIL TABLET (ORAL)	56.1%	ON	Yes-Generic			
NAMENDA TABLET DOSE PACK (ORAL)	0.1%	ON	Yes			
EXELON (TRANSDERM.)	5.8%	ON	Yes			
GALANTAMINE ER (ORAL)	0.8%	OFF	No-Generic			
NAMENDA TABLET (ORAL)	31.3%	ON	Yes			
GALANTAMINE TABLET (ORAL)	0.9%	OFF	No-Generic			
GALANTAMINE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
NAMENDA XR (ORAL)	2.5%	OFF	Yes		No	No
NAMENDA SOLUTION (ORAL)	0.1%	ON	Yes			
DONEPEZIL ODT (ORAL)	0.2%	ON	Yes-Generic			
RIVASTIGMINE CAPSULES (ORAL)	0.2%	ON	Yes-Generic			
ARICEPT 23 MG (ORAL)	0.1%	OFF	No			
EXELON CAPSULES (ORAL)	1.3%	ON	No			
DONEPEZIL 23 MG (ORAL)	0.4%	OFF	No-Generic			

- Discussion: Rick noted that production stopped this year for Namenda IR. No new generic expected until mid-2015.
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

ANTICONVULSANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLONAZEPAM (ORAL)	26.0%	ON	Yes-Generic			
CARBAMAZEPINE TABLET (ORAL)	2.2%	ON	Yes-Generic			
TOPIRAMATE TABLETS (ORAL)	12.4%	ON	Yes-Generic			
LAMOTRIGINE TABLET (ORAL)	18.3%	ON	Yes-Generic			
VALPROATE SYRUP (ORAL)	1.0%	ON	Yes-Generic			
PRIMIDONE (ORAL)	1.0%	ON	Yes-Generic			
CARBAMAZEPINE CHEWABLE TABLET (ORAL)	0.6%	ON	Yes-Generic			
DIVALPROEX TABLET (ORAL)	4.7%	ON	Yes-Generic			
CELONTIN (ORAL)	0.0%	ON	Yes			
VALPROIC ACID (ORAL)	0.2%	ON	Yes-Generic			
LEVETIRACETAM TABLETS (ORAL)	6.6%	ON	Yes-Generic			
EQUETRO (ORAL)	0.0%	OFF	No			
PHENOBARBITAL TABLET (ORAL)	1.0%	ON	Yes-Generic			
PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (ORAL)	0.0%	ON	Yes-Generic			
PHENYTOIN CAPSULE (ORAL)	1.5%	ON	Yes-Generic			
LEVETIRACETAM SOLUTION (ORAL)	2.5%	ON	Yes-Generic			
ZONISAMIDE (ORAL)	1.5%	ON	Yes-Generic			
OXCARBAZEPINE TABLETS (ORAL)	2.7%	ON	Yes-Generic			
GABITRIL (ORAL)	0.1%	ON	Yes			
LEVETIRACETAM ER (ORAL)	0.4%	ON	Yes-Generic			
DEPAKOTE SPRINKLE (ORAL)	1.5%	ON	Yes			
DILANTIN 30 MG CAPSULE (ORAL)	0.1%	ON	Yes-Generic			
PHENYTOIN SUSPENSION (ORAL)	0.1%	ON	Yes-Generic			
PEGANONE (ORAL)	0.0%	ON	Yes			
PHENYTOIN CHEWABLE TABLET (ORAL)	0.2%	ON	Yes-Generic			
LAMICTAL TABLET DOSE PACK (ORAL)	0.1%	ON	Yes			
TEGRETOL XR (ORAL)	0.7%	ON	Yes			
CLONAZEPAM ODT (ORAL)	0.1%	OFF	No-Generic			
DILANTIN INFATAB (ORAL)	0.1%	ON	Yes-Generic			
CARBAMAZEPINE XR (ORAL)	0.0%	OFF	No-Generic			
FELBATOL TABLET (ORAL)	0.3%	ON	Yes			
CARBATROL (ORAL)	0.5%	ON	Yes			
CARBAMAZEPINE SUSPENSION (ORAL)	0.2%	ON	Yes-Generic			
PHENOBARBITAL ELIXIR (ORAL)	0.5%	ON	Yes-Generic			
TRILEPTAL SUSPENSION (ORAL)	0.2%	ON	Yes			
ETHOSUXIMIDE SYRUP (ORAL)	0.2%	ON	Yes-Generic			
ETHOSUXIMIDE CAPSULE (ORAL)	0.2%	ON	Yes-Generic			
CARBAMAZEPINE ER (GENERIC CARBATROL) (ORAL)	0.7%	ON	Yes-Generic			
FELBATOL SUSPENSION (ORAL)	0.3%	ON	Yes			
PHENYTEK (ORAL)	0.0%	OFF	No-Generic			
TOPIRAMATE SPRINKLE (ORAL)	0.4%	ON	Yes-Generic			
DIASTAT (RECTAL)	0.0%	ON	Yes			
DIASTAT ACUDIAL (RECTAL)	0.5%	ON	Yes			
LAMICTAL ODT DOSE PACK (ORAL)	0.0%	OFF	No			
DIVALPROEX SPRINKLE (ORAL)	0.1%	OFF	No-Generic			
TIAGABINE (ORAL)	0.0%	OFF	No-Generic			
LAMOTRIGINE TABLET DOSE PACK (ORAL)	0.0%	ON	Yes-Generic			
DIVALPROEX ER (ORAL)	6.8%	ON	Yes-Generic			
DIAZEPAM (RECTAL)	0.0%	OFF	No-Generic			
STAVZOR (ORAL)	0.0%	OFF	No			
OXCARBAZEPINE SUSPENSION (ORAL)	0.4%	ON	Yes-Generic			
VIMPAT SOLUTION (ORAL)	0.1%	OFF	No			
VIMPAT TABLET (ORAL)	0.8%	OFF	No			
OXTELLAR XR (ORAL)	0.0%	OFF	No			
TOPIRAMATE ER (AG) (ORAL)	0.0%	NR	No-Generic			
LAMICTAL ODT (ORAL)	0.2%	OFF	No			
DIAZEPAM DEVICE (RECTAL)	0.0%	OFF	No-Generic			
ONFI TABLET (ORAL)	0.5%	OFF	No			
TROKENDI XR (ORAL)	0.0%	OFF	No			
BANZEL TABLET (ORAL)	0.2%	OFF	No			
LAMICTAL XR DOSE PACK (ORAL)	0.0%	OFF	No			
ONFI SUSPENSION (ORAL)	0.1%	OFF	No			
QUDEXY XR (ORAL)	0.0%	OFF	No			
POTIGA (ORAL)	0.0%	OFF	No			
LAMICTAL XR (ORAL)	0.3%	OFF	No			
FYCOMPA (ORAL)	0.0%	NR	No			
LAMOTRIGINE XR (ORAL)	0.3%	OFF	No-Generic			
FELBAMATE TABLET (ORAL)	0.1%	OFF	No-Generic			
APTIOM (ORAL)	0.0%	NR	No			
FELBAMATE SUSPENSION (ORAL)	0.0%	OFF	No-Generic			
BANZEL SUSPENSION (ORAL)	0.1%	OFF	No			
SABRIL POWDER PACK (ORAL)	0.1%	OFF	No			
SABRIL TABLET (ORAL)	0.0%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

ANTIDEPRESSANTS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VENLAFAXINE ER TABLETS (UPSTATE) (AG) (ORAL)	0.0%	OFF	No-Generic			
TRAZODONE (ORAL)	30.4%	ON	Yes-Generic			
MIRTAZAPINE TABLET (ORAL)	12.4%	ON	Yes-Generic			
VENLAFAXINE ER CAPSULES (ORAL)	21.1%	ON	Yes-Generic			
MARPLAN (ORAL)	0.0%	ON	Yes			
BUPROPION SR (ORAL)	11.7%	ON	Yes-Generic			
VENLAFAXINE (ORAL)	2.8%	ON	Yes-Generic			
MIRTAZAPINE ODT (ORAL)	0.4%	ON	Yes-Generic			
NEFAZODONE (ORAL)	0.1%	OFF	No-Generic			
BUPROPION XL (ORAL)	16.1%	ON	Yes-Generic			
BUPROPION (ORAL)	2.1%	ON	Yes-Generic			
PRISTIQ (ORAL)	1.2%	OFF	No			
PHENELZINE (ORAL)	0.0%	ON	Yes-Generic			
DESVENLAFAXINE ER (KHEDEZLA) (AG) (ORAL)	0.0%	NR	No-Generic			
VIIBRYD DOSE PACK (ORAL)	0.0%	OFF	No			
VIIBRYD (ORAL)	1.4%	OFF	No			
NARDIL (ORAL)	0.0%	ON	Yes			
VENLAFAXINE ER TABLETS (GENERIC) (ORAL)	0.0%	OFF	No-Generic			
OLEPTRO ER (ORAL)	0.0%	OFF	No			
DESVENLAFAXINE ER (ORAL)	0.0%	NR	No-Generic			
DESVENLAFAXINE FUMARATE ER (ORAL)	0.0%	NR	No-Generic			
FETZIMA (ORAL)	0.2%	NR	No			
VENLAFAXINE ER TABLETS (SCHWARZ) (AG) (ORAL)	0.1%	OFF	No-Generic			
KHEDEZLA (ORAL)	0.0%	OFF	No			
FORFIVO XL (ORAL)	0.0%	OFF	No			
BRINTELLIX (ORAL)	0.1%	NR	No			
TRANLYCYPROMINE SULFATE (ORAL)	0.0%	ON	Yes-Generic			
APLENZIN (ORAL)	0.0%	OFF	No			
EMSAM (TRANSDERMAL)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Lawrence Fleming
 - All members were in favor of this motion.
 - Motion passes

ANTIDEPRESSANTS, SSRIs						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SERTRALINE TABLET (ORAL)	31.5%	ON	Yes-Generic			
FLUOXETINE TABLET (ORAL)	3.8%	ON	Yes-Generic			
CITALOPRAM TABLET (ORAL)	20.9%	ON	Yes-Generic			
FLUOXETINE CAPSULE (ORAL)	22.2%	ON	Yes-Generic			
ESCITALOPRAM TABLET (ORAL)	9.0%	ON	Yes-Generic			
PAROXETINE TABLET (ORAL)	10.4%	ON	Yes-Generic			
FLUOXETINE SOLUTION (ORAL)	0.5%	ON	Yes-Generic			
FLUOXETINE 60 MG (ORAL)	0.2%	ON	Yes-Generic			
FLUVOXAMINE (ORAL)	0.8%	ON	Yes-Generic			
PEXEVA (ORAL)	0.0%	OFF	No			
CITALOPRAM SOLUTION (ORAL)	0.1%	ON	Yes-Generic			
LUVOX CR (ORAL)	0.0%	OFF	No			
SERTRALINE CONC (ORAL)	0.2%	ON	Yes-Generic			
BRISDELLE (ORAL)	0.0%	OFF	No			
PAROXETINE CR (ORAL)	0.1%	OFF	No-Generic			
PAXIL SUSPENSION (ORAL)	0.0%	ON	Yes			
FLUOXETINE CAPSULE DR (ORAL)	0.0%	OFF	No-Generic			
FLUVOXAMINE ER (ORAL)	0.0%	OFF	No-Generic			
ESCITALOPRAM SOLUTION (ORAL)	0.0%	ON	Yes-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

ANTIPARKINSON'S AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ROPINIROLE (ORAL)	28.3%	ON	Yes-Generic			
PRAMIPEXOLE (ORAL)	13.0%	ON	Yes-Generic			
BENZTROPINE (ORAL)	34.7%	ON	Yes-Generic			
TRIHEXYPHENIDYL TABLET (ORAL)	5.3%	ON	Yes-Generic			
MIRAPEX ER (ORAL)	0.0%	OFF	No			
TRIHEXYPHENIDYL ELIXIR (ORAL)	0.3%	ON	Yes-Generic			
COMTAN (ORAL)	0.1%	OFF	No			
CARBIDOPA / LEVODOPA (ORAL)	13.3%	ON	Yes-Generic			
CARBIDOPA / LEVODOPA ER (ORAL)	2.6%	ON	Yes-Generic			
ZELAPAR (ORAL)	0.0%	OFF	No			
SELEGILINE TABLET (ORAL)	0.1%	ON	Yes-Generic			
SELEGILINE CAPSULE (ORAL)	0.2%	ON	Yes-Generic			
CARBIDOPA / LEVODOPA ODT (ORAL)	0.2%	ON	Yes-Generic			
AZILECT (ORAL)	0.2%	OFF	No			
NEUPRO (TRANSDERM)	0.2%	OFF	No			
BROMOCRIPTINE (ORAL)	0.8%	ON	Yes-Generic			
LODOSYN (ORAL)	0.2%	ON	Yes			
TASMAR (ORAL)	0.0%	OFF	No			
REQUIP XL (ORAL)	0.0%	OFF	No			
ROPINIROLE ER (ORAL)	0.1%	OFF	No-Generic			
STALEVO (ORAL)	0.3%	ON	Yes			
ENTACAPONE (ORAL)	0.2%	OFF	No-Generic			
CARBIDOPA/LEVODOPA/ENTACAPONE (ORAL)	0.0%	OFF	No-Generic			
CARBIDOPA (ORAL)	0.0%	NR	Yes-Generic	No-Generic		

- Discussion: James Boblin stated that he did not see a need to have carbidopa recommended as preferred. It is not a burden to have one prescriber do a PA. Where do you draw the line? One member on carbidopa, 5 or 10 before we put PA on it. Kevin Izard commented that it is not necessary to put obstacles in the way. The committee should try to save the state money and manage safety issues. James Boblin recommended that we keep carbidopa non-preferred. Pat Towers also agreed that carbidopa should be non-preferred. She indicated that there are many other drugs that are non-preferred that are rarely used. Catherine Decker asked if brand name Lodosyn is carbidopa alone. Lynn Radmer confirmed that the brand Lodosyn is preferred and is carbidopa alone. She also added that the generic carbidopa recently came to market, and it is more expensive, but because of the low volume, we did not anticipate much utilization as a preferred drug.
- Pat Towers made a motion to accept staff recommendations but to have carbidopa remain non-preferred.
 - Second –James Boblin
 - All members were in favor of this motion.
 - Motion passes

ANTIPSYCHOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HALOPERIDOL LACTATE CONC (ORAL)	0.1%	ON	Yes-Generic			
RISPERIDONE TABLET (ORAL)	24.6%	ON	Yes-Generic			
QUETIAPINE TABLETS (ORAL)	27.8%	ON	Yes-Generic			
FLUPHENAZINE TABLET (ORAL)	0.8%	ON	Yes-Generic			
OLANZAPINE TABLET (ORAL)	7.4%	ON	Yes-Generic			
THIOTHIXENE (ORAL)	0.2%	ON	Yes-Generic			
THIORIDAZINE (ORAL)	0.2%	OFF	No-Generic			
ORAP (ORAL)	0.1%	ON	Yes			
HALOPERIDOL (ORAL)	3.5%	ON	Yes-Generic			
LOXAPINE (ORAL)	0.4%	ON	Yes-Generic			
TRIFLUOPERAZINE (ORAL)	0.2%	ON	Yes-Generic			
FANAPT TITRATION PACK (ORAL)	0.0%	OFF	No			
RISPERIDONE SOLUTION (ORAL)	0.7%	ON	Yes-Generic			
AMITRIPTYLINE / PERPHENAZINE (ORAL)	0.1%	ON	Yes-Generic			
FLUPHENAZINE ELIXIR/SOLN (ORAL)	0.0%	ON	Yes-Generic			
SEROQUEL XR (ORAL)	1.5%	OFF	No			
LATUDA (ORAL)	3.2%	ON	Yes			
PERPHENAZINE (ORAL)	0.3%	ON	Yes-Generic			
FANAPT TABLET (ORAL)	0.3%	OFF	No			
CLOZAPINE (ORAL)	2.9%	ON	Yes-Generic			
ZIPRASIDONE CAPSULE (ORAL)	7.2%	ON	Yes-Generic			
ADASUVE (INHALATION)	0.0%	NR	No			
OLANZAPINE ODT (ORAL)	0.5%	OFF	No-Generic			
CHLORPROMAZINE (ORAL)	0.6%	ON	Yes-Generic			
ABILIFY TABLET (ORAL)	14.9%	OFF	No			
RISPERIDONE ODT (ORAL)	0.7%	ON	Yes-Generic			
SAPHRIS (SUBLINGUAL)	0.4%	OFF	No			
FAZACLO (ORAL)	0.0%	OFF	No			
ABILIFY DISCMELT (ORAL)	0.1%	OFF	No			
SYMBYAX (ORAL)	0.0%	OFF	No			
ABILIFY SOLUTION (ORAL)	0.1%	OFF	No			
INVEGA (ORAL)	1.2%	OFF	No			
CLOZAPINE ODT (ORAL)	0.1%	OFF	No-Generic			
OLANZAPINE/FLUOXETINE (ORAL)	0.0%	OFF	No-Generic			
VERSACLOZ (ORAL)	0.0%	NR	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second –William Raduege
 - All members were in favor of this motion.
 - Motion passes

ANXIOLYTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DIAZEPAM TABLET (ORAL)	16.8%	ON	Yes-Generic			
LORAZEPAM TABLET (ORAL)	29.3%	ON	Yes-Generic			
ALPRAZOLAM TABLET (ORAL)	40.4%	ON	Yes-Generic			
CHLORDIAZEPOXIDE (ORAL)	0.5%	ON	Yes-Generic			
BUSPIRONE (ORAL)	11.0%	ON	Yes-Generic			
DIAZEPAM SOLUTION (ORAL)	0.5%	ON	Yes-Generic			
CLORAZEPATE (ORAL)	0.4%	ON	Yes-Generic			
ALPRAZOLAM ER (ORAL)	0.8%	ON	Yes-Generic			
DIAZEPAM INTENSOL (ORAL)	0.1%	OFF	No-Generic			
LORAZEPAM INTENSOL (ORAL)	0.2%	ON	Yes-Generic			
OXAZEPAM (ORAL)	0.1%	OFF	No-Generic			
ALPRAZOLAM INTENSOL (ORAL)	0.0%	ON	Yes-Generic			
ALPRAZOLAM ODT (ORAL)	0.0%	OFF	No-Generic			
NIRAVAM (ORAL)	0.0%	OFF	No			
MEPROBAMATE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Pat Towers
 - All members were in favor of this motion.
 - Motion passes

SEDATIVE HYPNOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZOLPIDEM (ORAL)	76.4%	ON	Yes-Generic			
TRIAZOLAM (ORAL)	0.8%	ON	Yes-Generic			
TEMAZEPAM (ORAL)	13.8%	ON	Yes-Generic			
FLURAZEPAM (ORAL)	0.2%	OFF	No-Generic			
ZALEPLON (ORAL)	2.1%	ON	Yes-Generic			
SILENOR (ORAL)	0.0%	OFF	No			
ESTAZOLAM (ORAL)	0.5%	ON	Yes-Generic			
ESZOPICLONE (ORAL)	1.6%	OFF	No-Generic			
INTERMEZZO (SUBLINGUAL)	0.0%	OFF	No			
ROZEREM (ORAL)	1.8%	ON	Yes			
ZOLPIMIST (ORAL)	0.0%	OFF	No			
ZOLPIDEM ER (ORAL)	2.7%	OFF	No-Generic			
EDLUAR (SUBLINGUAL)	0.0%	OFF	No			
TEMAZEPAM 7.5 MG (ORAL)	0.1%	OFF	No-Generic			
TEMAZEPAM 22.5 MG (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

STIMULANTS AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METADATE CD (ORAL)	2.2%	ON	Yes			
DEXEDRINE SPANSULE (ORAL)	0.1%	ON	Yes			
FOCALIN (ORAL)	0.1%	ON	Yes			
FOCALIN XR (ORAL)	4.5%	ON	Yes			
DEXMETHYLPHENIDATE (ORAL)	0.8%	ON	Yes-Generic			
METHYLPHENIDATE (ORAL)	6.8%	ON	Yes-Generic			
VYVANSE (ORAL)	15.0%	ON	Yes			
AMPHETAMINE SALT COMBO (ORAL)	7.6%	ON	Yes-Generic			
RITALIN SR (ORAL)	0.0%	ON	Yes			
RITALIN LA (ORAL)	0.1%	OFF	No			
STRATTERA (ORAL)	3.5%	ON	Yes			
DAYTRANA (TRANSDERMAL)	0.8%	ON	Yes			
METHYLPHENIDATE ER (ORAL)	1.3%	ON	Yes-Generic			
METHYLIN CHEWABLE TABLETS (ORAL)	0.0%	ON	Yes			
KAPVAY (ORAL)	0.1%	OFF	No			
RITALIN LA 10 MG CAPSULE (ORAL)	0.0%	OFF	No			
ADDERALL XR (ORAL)	25.6%	ON	Yes			
ZENZEDI (ORAL)	0.0%	OFF	No-Generic			
INTUNIV (ORAL)	5.1%	ON	Yes			
QUILLIVANT XR (ORAL)	0.3%	ON	Yes			
DESOXYN (ORAL)	0.0%	OFF	No			
NUVIGIL (ORAL)	0.0%	OFF	No			
PROCENTRA (ORAL)	0.0%	ON	Yes-Generic			
METHYLPHENIDATE CD (AG) (ORAL)	0.0%	OFF	No-Generic			
AMPHETAMINE SALT COMBO ER (AG) (ORAL)	0.0%	OFF	No-Generic			
DEXMETHYLPHENIDATE XR (ORAL)	0.0%	NR	No-Generic			
METHYLPHENIDATE ER (CONCERTA) (AG) (ORAL)	9.1%	ON	Yes-Generic			
AMPHETAMINE SALT COMBO ER (ORAL)	0.0%	OFF	No-Generic			
DEXMETHYLPHENIDATE XR (AG) (ORAL)	0.0%	NR	No-Generic			
DEXTROAMPHETAMINE TABLET (ORAL)	0.7%	ON	Yes-Generic			
METHYLPHENIDATE ER (GEN RITALIN LA) (ORAL)	0.1%	OFF	No-Generic			
METHYLPHENIDATE ER (CONCERTA) (ORAL)	3.8%	ON	Yes-Generic			
METHYLIN SOLUTION (ORAL)	0.0%	OFF	No			
METHYLPHENIDATE CD (ORAL)	0.0%	OFF	No-Generic			
ADDERALL	10.7%	ON	Yes-Generic			
CLONIDINE ER (ORAL)	0.3%	NR	No-Generic			
DEXTROAMPHETAMINE CAPSULE ER (ORAL)	1.0%	ON	Yes-Generic			
METHYLPHENIDATE SOLUTION (AG) (ORAL)	0.0%	OFF	No-Generic			
METHYLPHENIDATE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
DEXTROAMPHETAMINE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
MODAFINIL (ORAL)	0.1%	OFF	No-Generic			
METHAMPHETAMINE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second –Catherine Decker
 - All members were in favor of this motion.
 - Motion passes

GLUCOCORTICOIDS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PREDNISONE TABLET (ORAL)	66.5%	NR	Yes-Generic			
PREDNISOLONE SOLUTION (ORAL)	5.8%	NR	Yes-Generic			
PREDNISOLONE SODIUM PHOSPHATE (ORAL)	9.4%	NR	Yes-Generic			
PREDNISONE TAB DS PK (ORAL)	0.0%	NR	Yes-Generic			
DEXAMETHASONE TABLET (ORAL)	3.6%	NR	Yes-Generic			
METHYLPREDNISOLONE 32 MG TABLET (ORAL)	0.1%	NR	Yes-Generic			
DEXAMETHASONE SOLUTION (ORAL)	0.1%	NR	Yes-Generic			
PREDNISONE SOLUTION (ORAL)	0.3%	NR	Yes-Generic			
DEXAMETHASONE INTENSOL (ORAL)	0.2%	NR	Yes-Generic			
DEXAMETHASONE ELIXIR (ORAL)	0.1%	NR	Yes-Generic			
DEXPAK (ORAL)	0.0%	NR	No-Generic			
METHYLPREDNISOLONE TAB DS PK (ORAL)	9.9%	NR	Yes-Generic			
HYDROCORTISONE (ORAL)	2.2%	NR	Yes-Generic			
VERIPRED 20 (ORAL)	0.0%	NR	No			
METHYLPREDNISOLONE TABLET (ORAL)	0.3%	NR	Yes-Generic			
MEDROL TABLET (ORAL)	0.0%	NR	No			
CORTEF (ORAL)	0.1%	NR	No			
PREDNISONE INTENSOL (ORAL)	0.0%	NR	Yes-Generic			
METHYLPREDNISOLONE 16 MG TABLET (ORAL)	0.0%	NR	Yes-Generic			
METHYLPREDNISOLONE 8 MG TABLET (ORAL)	0.0%	NR	Yes-Generic			
MILLIPRED SOLUTION (ORAL)	0.0%	NR	No-Generic			
CORTISONE (ORAL)	0.0%	NR	No-Generic			
MILLIPRED DP TAB DS PK (ORAL)	0.0%	NR	No-Generic			
ENTOCORT EC (ORAL)	0.0%	NR	Yes			
FLO-PRED (ORAL)	0.0%	NR	No			
RAYOS TABLET DR (ORAL)	0.0%	NR	No			
PEDIAPRED (ORAL)	0.0%	NR	No-Generic			
MILLIPRED TABLET (ORAL)	0.0%	NR	No-Generic			
BUDESONIDE EC (ORAL)	1.2%	NR	No-Generic			

- Discussion: Catherine Decker questioned why this was added as a new class. Rick Pope stated that Magellan evaluates different classes from time to time and it was determined that having a PDL class for these drugs will result in cost savings for the state.
- Lawrence Fleming made a motion to accept staff recommendations as presented.
 - Second –Kevin Izard
 - All members were in favor of this motion.
 - Motion passes